
    
      This is a multi-center, randomized, double-blind, placebo-controlled, parallel-group study
      with an open-label extension. The study consists of 3 phases; screening phase (1 to 4 weeks),
      double-blind phase (24 weeks), and Open-label extension phase (24 weeks). Participants, who
      have completed the double-blind phase and want to continue the study participation, can be
      enrolled in the 24-week open-label extension phase.
    
  